INDP
Indaptus Therapeutics, Inc. [INDP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INDP Stock Summary
Top 10 Correlated ETFs
INDP
Top 10 Correlated Stocks
INDP
In the News
INDP Financial details
Company Rating
-
Market Cap
23.65M
Income
-15.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-1.09
Forward P/E
-
PEG
-1.13
P/S
-
P/B
1.03
P/C
-
P/FCF
-1.21
Quick Ratio
6.75
Current Ratio
7.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.82
EPS next Y
-
EPS next Q
-
EPS this Y
10.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
2.13%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-72%
ROC
-1.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.56-4.08
52W High
-87%
52W Low
-48.01%
RSI
27
Rel Volume
0.85
Avg Volume
86.05K
Volume
73.17K
Perf Week
-27.08%
Perf Month
-32.48%
Perf Quarter
-53.16%
Perf Half Y
-60.01%
-
-
-
-
Beta
1.225
-
-
Volatility
0.04%, 0.1%
Prev Close
-5.46%
Price
0.5199
Change
-7.33%
Company Profile
- Volume Average 86.05K
- Market Capitalization 23.65M
- Employee 7
- CEO Mr. Jeffrey A. Meckler
- Headquarters New York,NY,US
- IPO Date 2015-08-04
-
Website
https://indaptusrx.com 
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
